SLS
SELLAS Life Sciences Group, Inc.
1.46
-
0.06
3.95%
8 x 1.44
8 x 1.47
bid
ask
8 @ 04:00 PM
1.46+0.00 (0.00%)
Bearish
29
Bullish
115
sentiment
1.42
day range
1.54
0.51
52 week range
1.83
Prev Close1.52
Open1.53
Low1.42
High1.54
Volume1.28M
Avg. Volume1.47M
Market Cap82.15M
Inst. Own10.32%
Beta2.37
Short Ratio2.84
Div & Yield0.00 /
EPS-1.34
P/E0.00
1yr Target6.83
50day MA1.19
200day MA1.18
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | 0 | N/A | N/A | N/A |
2024-03-28 | 2023-12 | 0 | -0.25 | N/A | N/A |
2023-11-09 | 2023-09 | 0 | -0.33 | N/A | N/A |
2023-08-10 | 2023-06 | 0 | -0.31 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -0.47 | N/A | N/A |
2023-03-16 | 2022-12 | 0 | -0.43 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-11-14 | Alliance Global Partners | Upgrade | Buy | |
2022-06-27 | Cantor Fitzgerald | Upgrade | Overweight | |
2021-07-20 | Cantor Fitzgerald | Upgrade | Overweight | |
2019-11-14 | Maxim Group | Upgrade | Hold | Buy |
2019-04-07 | Alliance Global Partners | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-21 | BURNS JOHN THOMAS | Chief Financial Officer | 101.93K | Stock Award(Grant) |
2024-01-21 | FRANCOMANO ROBERT | Officer | 40.92K | Stock Award(Grant) |
2024-01-21 | KALIN KATHERINE BACH | Director | 8.50K | Stock Award(Grant) |
2017-12-28 | LOPEZ FABIO | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2024-01-21 | SCHEINBERG DAVID A | Director | 10.58K | Stock Award(Grant) |
2024-01-21 | STERGIOU ANGELOS M | Chief Executive Officer | 376.42K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Alyeska Investment Group, L.p. | 1.25M | 1.96M | 4.41% |
2023-06-29 | Vanguard Group Inc | 946.71K | 1.49M | 3.34% |
2023-06-29 | Blackrock Inc. | 283.37K | 444.89K | 1.00% |
2023-06-29 | Geode Capital Management, LLC | 188.07K | 295.26K | 0.66% |
2023-06-29 | Equitable Holdings, Inc. | 135.00K | 211.95K | 0.48% |
2023-06-29 | State Street Corporation | 97.13K | 152.49K | 0.34% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 592.27K | 929.87K | 2.09% |
2023-06-29 | Vanguard Extended Market Index Fund | 318.24K | 499.64K | 1.12% |
2023-05-30 | Fidelity Extended Market Index Fund | 101.70K | 174.42K | 0.36% |
2023-08-30 | iShares Micro Cap ETF | 63.00K | 92.61K | 0.22% |
2023-05-30 | Fidelity Total Market Index Fund | 36.80K | 63.11K | 0.13% |
2023-05-30 | Fidelity Series Total Market Index Fund | 25.07K | 43.00K | 0.09% |
Dividend
...
Dividend | Date |
---|---|
0.42 | 2010-12-09 |
0.15 | 2010-09-09 |
Split
...
Split | Date |
---|---|
1 : 50 | 2019-11-08 |
1 : 50 | 2019-11-06 |
1 : 30 | 2018-01-02 |
1 : 30 | 2018-01-01 |
1 : 20 | 2016-11-14 |
This topic has been deleted. Only users with topic management privileges can see it.
-
$SLS Lots of sellers, this could turn back and crush 30!
-
$SLS if we hold tight, there might be no lunch break for the big boys
-
$SLS please hold dammit
-
Hold dammit!
-
This will probably flirt between .21-.25 for hours as people keep buying and panic selling or shorting for pennies. I believe this realistically could hit the .30’s today if this volume continues
-
Is it the last dip or it will go lower still ?
-
Sell off
-
What’s a good entry point folks ?
-
-
Stop the
-
Waiting out .40
-
-
-
-
-
-
-
-
Closing Bell: Solaris Resources Inc down on Friday (SLS)
news.google.com • -
Closing Bell: Solaris Resources Inc up on Wednesday (SLS)
news.google.com • -
Closing Bell: Solaris Resources Inc down on Monday (SLS)
news.google.com • -
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
seekingalpha.com • -
Why Is Sellas Life Sciences (SLS) Stock Down 25% Today?
investorplace.com • -
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
globenewswire.com • -
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
investorplace.com • -
SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021
globenewswire.com • -
SELLAS Life Sciences Announces Settlement of Derivative Litigation
globenewswire.com • -
SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
globenewswire.com • -
What's Up With Sellas Life Sciences Stock Today?
benzinga.com • -
SELLAS Life Sciences to Host Shareholder Update Call on June 3rd
globenewswire.com • -
Sellas: Late-Stage Biotech Approaches 2023 Approval With Solid Funding
seekingalpha.com • -
SLS Stock: 8 Things to Know About SELLAS Life Sciences as It Enjoys Reddit Bump
investorplace.com • -
Shares of Startup Biotechs Soar on Cancer Study Results
gurufocus.com • -
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
globenewswire.com •